BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer
NCT00022477 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2013-09-05
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have recurrent or metastatic colorectal cancer.
Conditions
Interventions
- DRUG
-
BMS-247550
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
University of Chicago
lead OTHER
Principal Investigators
-
Hedy L. Kindler, MD · University of Chicago
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2001-09-30
- Primary Completion
- 2002-10-31
- Completion
- 2004-12-31
Countries
- United States
Study Locations
More Related Trials
-
Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer
NCT07011550 ·Status: SUSPENDED ·Phase: PHASE2
-
Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer
NCT00111761 ·Status: COMPLETED ·Phase: PHASE2
-
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
NCT04017650 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
NCT00005085 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
NCT05608044 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment
NCT00717990 ·Status: TERMINATED ·Phase: PHASE2
-
Palbociclib and Cetuximab in Metastatic Colorectal Cancer
NCT03446157 ·Status: COMPLETED ·Phase: PHASE2
-
Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer
NCT00003225 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer
NCT00003220 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer
NCT00116506 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
NCT01767857 ·Status: TERMINATED ·Phase: PHASE3
-
Ro 31-7453 in Treating Patients With Recurrent or Refractory Metastatic Colorectal Cancer
NCT00016250 ·Status: COMPLETED ·Phase: PHASE2
-
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
NCT04587128 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma
NCT00111774 ·Status: COMPLETED ·Phase: PHASE2
-
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
NCT04117945 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
NCT01103323 ·Status: COMPLETED ·Phase: PHASE3
-
Bortezomib in Treating Patients With Metastatic or Recurrent Colorectal Cancer
NCT00052507 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
NCT04708470 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer
NCT03542877 ·Status: COMPLETED ·Phase: PHASE2
-
Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy
NCT05672316 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer
NCT00032110 ·Status: COMPLETED ·Phase: PHASE2
-
Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer
NCT00017082 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
NCT05217446 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
NCT00207155 ·Status: COMPLETED ·Phase: PHASE1
-
Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer
NCT03290937 ·Status: COMPLETED ·Phase: PHASE1